These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 18642109)

  • 21. Antifungal therapy in invasive fungal infections.
    Chen SC; Playford EG; Sorrell TC
    Curr Opin Pharmacol; 2010 Oct; 10(5):522-30. PubMed ID: 20598943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fungal infections.
    Kauffman CA
    Proc Am Thorac Soc; 2006; 3(1):35-40. PubMed ID: 16493149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Invasive fungal infections in patients after liver transplantation].
    Fischer L; Sterneck M
    Mycoses; 2005; 48 Suppl 1():27-35. PubMed ID: 15826284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.
    Strasfeld L; Weinstock DM
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of invasive fungal infections: a role for polyenes.
    Chandrasekar P
    J Antimicrob Chemother; 2011 Mar; 66(3):457-65. PubMed ID: 21172787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Posaconazole: clinical pharmacology and potential for management of fungal infections.
    Groll AH; Walsh TJ
    Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Posaconazole: a broad-spectrum triazole antifungal.
    Torres HA; Hachem RY; Chemaly RF; Kontoyiannis DP; Raad II
    Lancet Infect Dis; 2005 Dec; 5(12):775-85. PubMed ID: 16310149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current therapeutic approaches to fungal infections in immunocompromised hematological patients.
    Pagano L; Caira M; Valentini CG; Posteraro B; Fianchi L
    Blood Rev; 2010 Mar; 24(2):51-61. PubMed ID: 20056300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Drug resistance in the treatment of invasive fungal infections].
    Nordøy I; Gaustad P
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2607-11. PubMed ID: 19023376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
    Steinbach WJ; Reedy JL; Cramer RA; Perfect JR; Heitman J
    Nat Rev Microbiol; 2007 Jun; 5(6):418-30. PubMed ID: 17505522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections.
    Lewis RE
    Am J Ther; 2012 Jan; 19(1):51-63. PubMed ID: 21248618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of new antifungal agents.
    Kauffman CA
    Curr Opin Microbiol; 2006 Oct; 9(5):483-8. PubMed ID: 16904366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antifungal agents in the treatment of systemic infections: Relevance of mechanism of action, activity profile and resistances].
    Cuenca-Estrella M
    Rev Esp Quimioter; 2010 Dec; 23(4):169-76. PubMed ID: 21191554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of antifungal susceptibility testing in patient management.
    Forrest G
    Curr Opin Infect Dis; 2006 Dec; 19(6):538-43. PubMed ID: 17075328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
    Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
    Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
    Groll AH; Walsh TJ
    Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changing epidemiology of rare mould infections: implications for therapy.
    Malani AN; Kauffman CA
    Drugs; 2007; 67(13):1803-12. PubMed ID: 17722951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fungal infections in neonates: update on prevention and treatment.
    Kaufman DA
    Minerva Ginecol; 2007 Jun; 59(3):311-29. PubMed ID: 17576407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.
    Slavin MA; Szer J; Grigg AP; Roberts AW; Seymour JF; Sasadeusz J; Thursky K; Chen SC; Morrissey CO; Heath CH; Sorrell T
    Intern Med J; 2004 Apr; 34(4):192-200. PubMed ID: 15086700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.